Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Widespread extracellular electron transfer pathways at the interface of bimetallic metal-organic frameworks composite bioanode.

Bioresource technology·2026

Same author

From network prediction to in vivo validation: luteolin attenuates cholestatic liver injury in association with PI3K/Akt/GSK-3β signalling modulation.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Same author

Revealing the lagged relationship between groundwater changes and land subsidence in Tianjin based on GRACE and InSAR observations.

Scientific reports·2026

Same author

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota-Dependent Manner.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Implication of genetic-dependent stage in the development of <i>SCN8A</i>-associated epilepsy: a case report.

Frontiers in human neuroscience·2026

Same author

Broad-spectrum antimicrobial activity of a citric acid-phenolic formulation in animal feed matrices.

Frontiers in microbiology·2026

Search research articles

Related Experiment Video

Updated: Sep 3, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

[Blocking Adenosine/A2AR Pathway for Cancer Therapy].

Jia Liu¹, Yuequan Shi¹, Xiaoyan Liu¹

¹Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer

|July 28, 2022

Summary

This summary is machine-generated.

Blocking the adenosine A2A receptor (A2AR) pathway shows promise for enhancing anti-tumor immunity. Clinical trials indicate A2AR antagonists are safe and effective in cancer patients, alone or combined with other treatments.

Keywords:

A2AR antagonist Adenosine Adenosine receptor Tumor microenvironment

More Related Videos

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Related Experiment Videos

Last Updated: Sep 3, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Area of Science:

Immunology
Oncology
Pharmacology

Background:

Adenosine, abundant in the tumor microenvironment, suppresses immune responses via the adenosine A2A receptor (A2AR).
A2AR is expressed on immune cells, inhibiting anti-tumor immunity.
Blocking the adenosine signaling pathway presents a therapeutic strategy to enhance anti-tumor immunity.

Purpose of the Study:

To review the adenosine signaling pathway and its role in tumor immunity.
To highlight the therapeutic potential of adenosine A2A receptor (A2AR) blockade in cancer therapy.

Main Methods:

Review of preclinical data on adenosine/A2AR inhibition.
Analysis of ongoing and completed clinical trials of A2AR antagonists.
Evaluation of safety and efficacy of A2AR antagonists as monotherapy and in combination.

Main Results:

Preclinical studies demonstrate prospective anti-tumor activity of adenosine/A2AR inhibition.
Clinical trials show A2AR antagonists are well-tolerated in cancer patients.
A2AR antagonists demonstrate efficacy as monotherapy and in combination regimens.

Conclusions:

Adenosine A2A receptor (A2AR) blockade is a promising strategy for cancer immunotherapy.
Further research is needed to identify predictive biomarkers for patient selection.
Rational combination strategies involving A2AR antagonists require further investigation.